Praluent partners Sanofi and Regeneron have been battling for market share against Amgen’s Repatha in the PCSK9 class of cholesterol drugs, including by recently lowering their price. Now, the ...
It’s no secret that the two existing PCSK9 cardiovascular drugs on the market, Amgen’s Repatha and Regeneron and Sanofi’s Praluent, are suffering from painfully slow launches. And on top of that, they ...
In business parlance, a bolt-on acquisition is one in which the smaller company offers its acquirer strategic value. Swiss drugmaker Novartis’ recently announced $9.7 billion takeover of The Medicines ...
The marketing battle over the newest drugs to lower cholesterol levels is on. Source: Regeneron Pharmaceuticals. Sanofiand Regeneron Pharmaceuticals' Praluent was approved by the Food and Drug ...
Regeneron and Sanofi will cut the price of their cholesterol drug Praluent by 60 percent to $5,850 a year, matching an unprecedented move that rival Amgen made with its medicine Repatha, the drug ...
LONDON, July 24 (Reuters) - A new type of cholesterol drug from Sanofi and Regeneron Pharmaceuticals won a green light from European regulators on Friday, two months behind a rival product from Amgen.
The PCSK9 drugs are stirring up a lot of attention, primarily around how to restrict access. But, no one is talking about how to best manage the patient's needs. The PCSK9 drugs continue to remain in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results